secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001108205-25-000045
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q1 net loss $10.6M, appoints Dr. Hamdy CMO, emavusertib progress
----------------------------------------------------------------------

- Net loss $10.6M ($1.25/share); cash $20.3M; runway into Q4 2025.
- Revenue $2.4M from Genentech/Roche Erivedge royalties.
- Appointed Dr. Ahmed Hamdy (ex-Pharmacyclics, Acerta) as CMO.
- FDA & EMA meetings support accelerated approval path for emavusertib in PCNSL.
- Completed registered direct offering and private placement with net proceeds ~$8.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820525000045/0001108205-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820525000045/cris-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001108205-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer